Skip to content
Menu

Revelation Biosciences, Inc. REVB

Full chart Compare
Set alert

Price alert · REVB

All alert types
3.50 USD -0.19 (-5.15%)

Regular-session close

3.69 +0.19 +5.43%

After hours · Nov 20, 4:00 PM ET

3.50 Day range 3.80
3.08 52-week range 40.60
YTD
+9.37%
1 year
+2.94%

5D -0.26 (-6.09%)

44.50ThuFriMonTueWed4.01
Market cap
1.99M
EPS (ttm)
-99.96
Shares out
8.36M
Forward P/E
-0.13
YTD return
+9.37%
1-year return
+2.94%
50-day average
0.7149
Volume
9.80K
Avg volume
12.36K
Open
3.71
Previous close
3.69
Day's range
3.50 – 3.80
52-week range
3.08 – 40.60
Price target
12.75 (+264.3%)

Key statistics

200-day average
1.49
Enterprise value
-5.27M
Price / book
0.49
Free cash flow
-6.49M
Total cash
6.54M
Return on equity
-270.02%
Short % of float
2.93%

Fundamental scorecard

4 of 25 checks passed on REVB’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
REVB Revenue — quarterly 0
REVB Net income — quarterly -3.32M
REVB EPS — quarterly -5.92

Earnings

REVB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 8, 2024Sep 1, 2024-2.84-0.84+2.00+70.42%
Aug 9, 2024Jun 1, 2024-1.81-1.54+0.27+14.92%
Aug 9, 2024Jun 1, 2024-1.81———
May 10, 2024Mar 1, 2024-5.39-2.46+2.93+54.36%
May 10, 2024Mar 1, 2024-5.39———
Mar 22, 2024Dec 1, 2023-10.94-8.33+2.61+23.86%

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on REVB — it syncs with the Stock Master app.

Insider holders

REVB insider holders
InsiderRelationLatest transactionDateShares held
TIDMARSH GEORGE FDirectorSaleDec 7, 202342,096

Institution ownership

REVB institution ownership
Holder% heldSharesValueReported
Sabby Management, LLC0.51%42,22612.77KSep 29, 2024
UBS Group AG0.49%40,94512.38KSep 29, 2024
Susquehanna International Group, LLP0.16%13,2584.01KSep 29, 2024
Tower Research Capital LLC (TRC)0.03%2,539767Sep 29, 2024
Pom Investment Strategies, LLC 0.00%10Sep 29, 2024
Bank of America Corporation0.00%298Sep 29, 2024

Fund ownership

REVB fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.10%8,0222.42KOct 30, 2024
Fidelity Series Total Market Index Fund0.04%2,942889Oct 30, 2024
Vanguard Extended Market Index Fund0.00%20160Sep 29, 2024